



09/502 945

COFC

DOCKET NO.: L0461.70081US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Matthew J. Scanlan et al.
Patent No.: 6,982,316 B1
Serial No.: 09/502,945
Confirmation No.: 5906
Filed: February 11, 2000
For: ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED WITH
COLON CANCER AND METHODS FOR DIAGNOSING AND
TREATING COLON CANCER
Examiner: Misook Yu
Art Unit: 1642

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Mail Stop Certificate of Correction, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 12th day of January, 2006.

Melissa L. Barlow Lyons
Melissa L. Barlow Lyons

Mail Stop Certificate of Correction

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Request for Certificate of Correction Under 37 C.F.R. § 1.322
- Certificate of Correction - Form PTO-1050
- Copy of pertinent pages from U.S. Patent No. US 6,982,316 B1
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,
Matthew J. Scanlan et al., Applicant

By:

Mary Dilys S. Anderson
Mary Dilys S. Anderson, Ph.D., Reg. No.: 52,560
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: L0461.70081US00
Date: January 12, 2006
xNDDx
976747.1

Certificate
JAN 20 2006
of Correction

FEB 2 2006



DOCKET NO.: L0461.70081US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Matthew J. Scanlan et al.
Patent No.: 6,982,316 B1
Serial No.: 09/502,945
Confirmation No.: 5906
Filed: February 11, 2000
For: ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED WITH
COLON CANCER AND METHODS FOR DIAGNOSING AND
TREATING COLON CANCER
Examiner: Misook Yu
Art Unit: 1642

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Mail Stop Certificate of Correction, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 12th day of January, 2006.


Melissa L. Barlow Lyons

Mail Stop Certificate of Correction
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE
OF CORRECTION UNDER 37 C.F.R. §1.322 and § 1.323


Sir/Madam:

Patentees respectfully request the correction of errors found in the printing of the above-captioned patent. The corrections made to the abstract and to claims 12 rectify typographical errors made by the Patent Office. In the abstract, line 2, "aid" should be replaced with "and". In claim 12, lines 1 and 2, the phrase "at least one" should not be in the claim as it was removed from the claim in the amendment filed on February 16, 2005.

FEB 2 2006

Patentees point out that the corrections requested do not involve changes in the patent that constitutes new matter or would require reexamination, and therefore, respectfully request that a certificate of correction be issued. Patentee encloses copies of the patent pages with the errors highlighted. A check is not enclosed. If a fee is deemed necessary, the fee may be charged to the account of the undersigned, Deposit Account No. 23/2825. Should any questions arise concerning the foregoing, please contact the undersigned at the telephone number listed below.

Respectfully submitted,
Matthew J. Scanlan et al., Applicant

By: 
MaryDilys S. Anderson, Ph.D., Reg. No.: 52,560
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: L0461.70081US00
Date: January 12, 2006
xNDDx

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : US 6,982,316 B1
DATE : January 3, 2006
INVENTORS : Matthew J. Scanlan et al.

It is certified that the error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the abstract:

Line 2 should read as shown below.

--are disclosed. The invention also discloses a diagnostic and--

In the claims:

Claim 12, lines 1 and 2 should read as shown below.

--The composition of matter of claim 2, wherein the--
--nucleic acid molecule consists of the nucleotide--

MAILING ADDRESS OF SENDER:

MaryDilys S. Anderson
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211

PATENT NO. US 6,982,316 B1

FEB 2 2006



US006982316B1

(12) **United States Patent**
Scanlan et al.

(10) Patent No.: **US 6,982,316 B1**
(45) Date of Patent: **Jan. 3, 2006**

(54) **ISOLATED NUCLEIC ACID MOLECULES
ASSOCIATED WITH COLON CANCER AND
METHODS FOR DIAGNOSING AND
TREATING COLON CANCER**

(75) Inventors: **Matthew J. Scanlan**, New York, NY
(US); **Yao-Tseng Chen**, New York, NY
(US); **Elisabeth Stockert**, New York,
NY (US); **Lloyd J. Old**, New York, NY
(US)

(73) Assignees: **Ludwig Institute for Cancer
Research**, New York, NY (US); **The
New York Hospital-Cornell Medical
Center**, New York, NY (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/502,945**

(22) Filed: **Feb. 11, 2000**

Related U.S. Application Data

(62) Division of application No. 08/948,705, filed on Oct.
10, 1997, now Pat. No. 6,043,084.

(51) Int. Cl.
C07K 14/47 (2006.01)
C07K 7/00 (2006.01)

(52) U.S. Cl. **530/350; 530/300; 424/184.1**

(58) Field of Classification Search **424/277.1,**
424/184.1; 530/350, 300

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,470,730 A * 11/1995 Greenberg et al.
5,698,396 A 12/1997 Pfreundschuh
5,840,839 A * 11/1998 Wang et al. 530/325
6,025,191 A 2/2000 Pfreundschuh

OTHER PUBLICATIONS

Sahin et al., *Proc. Natl. Acad. Sci.*, vol. 92, pp. 11810-11813,
Dec. 1995.*
Alberts, et al. (*Molecular Biology of the Cell*, 3rd edition,
1994.*
Scanlan et al (1998, *Int. J. Cancer*, vol. 76, pp. 652-658.*
Riott et al (*Immunology*, Fourth Edition, 1996, Mosby, p.
7.9-7.11.*
Peltz et al p. 1729 (1999, *J. Exp. Med.* vol. 190, pp.
1729-1731).*
de Plaen et al., *Proc. Natl. Sci. USA* 85:2275, 1988.
Mandelboim et al., *Nature* 369:69 1994.
van der Bruggen et al., *Science* 254:1643-1647, 1991.
Brichard et al., *J. Exp. Med.* 178:489-495, 1993.
Coulie et al., *J. Exp. Med.* 180:35-42, 1994.
Kawakami et al., *Proc. Natl. Acad. Sci. USA* 91:3515-3519,
1994.
Oettgen et al., *Immunol. Allerg. Clin. North. Am.* 10:607-
637, 1990.
Sahin et al., *Proc. Natl. Acad. Sci. USA* 92:11810-11913,
1995.
Crew et al., *EMBO J* 144:2333-2340, 1995.
Chen et al., *Proc. Natl. Acad. Sci. USA* 94: 1914-1918
(1997).

* cited by examiner

Primary Examiner—Jeffrey Siew

Assistant Examiner—Misook Yu

(74) *Attorney, Agent, or Firm*—Wolf, Greenfield & Sacks
P.C.

(57) **ABSTRACT**

Various molecules associated with disorders such as cancer
are disclosed. The invention also discloses diagnostic aid
therapeutic methods based upon these molecules, as well as
compositions for stimulating an immune response and meth-
ods for identifying cancer-associated nucleic acid and
polypeptide molecules.

14 Claims, No Drawings

FEB 2 2006

-continued

```

aagtttaaga agcaatggga agaagactgg ggctcaaagg aacagctact cttgcctaaa 1260
accatcactg ctgaggtaca cccagtaccc cttcgcaagc caaagtatga tcaggagagt 1320
gaacctgagc tcgagcccg agatgacctg gatggaggca cggaggagca gggagagcag 1380
ccacaggaga tgttgaagag gatggtggtt tatcaagaca gcattcaaga caagatttcc 1440
ggaaatatga ggaaggcttt gacccctact ctatgttcac cccagagcag atcatgggga 1500
aggatgtccg gctcctacgc atcaagaagg agggatcctt agacctggcc ctggaaggcg 1560
gtgtggactc cccattggg aaggtggtcg tttctgctgt gtatgagcgg ggagctgctg 1620
agcggcatgg tggcattgtg aaaggggacg agatcatggc aatcaacggc aagattgtga 1680
cagactacac cctggctgag gctgacgctg cctgcagaa ggcctggaat cagggcgggg 1740
actggatcga ccttgtggtt gccgtctgcc ccccaaagga gtatgacgat gagctgacct 1800
tcttgctgaa gtccaaaagg ggaaccacaa ttcacgcgtt aggaacacgt gagctccggc 1860
cccacctcgt gaacacaaag cctcggaaca gccttgagag aggccacatg acacacacca 1920
gatggcatcc ttgggacctg aatctatcac ccaggaatct caaactccct ttggccctga 1980
accagggccg gataaggaac agctcgggcc acttttttga aggccaatgt ggaggaaagg 2040
gagcagccag ccgtttggga gaagatctca aggatccaga ctctcattcc tttctctg 2100
cccagtgaat ttggtctctc ccagctttgg gggactcctt ccttgaacce taataagacc 2160
ccactggagt ctctctctct ccatecctct cctctgccct ctgctcta atgtgccagg 2220
attgtcactc caaaccttac tctgagctca ttaataaaat aaacagattt attttccagc 2280
ttaaaaaaa 2289

```

35

We claim:

1. An isolated protein encoded by an isolated nucleic acid molecule selected from the group consisting of: SEQ ID NOs: 1, 2, 3, 4 and 5.

2. A composition of matter comprising a protein encoded by a nucleic acid molecule selected from the group consisting of SEQ ID NO: 1, 2, 3, 4 and 5.

3. The composition of matter of claim 2, further comprising an adjuvant.

4. The composition of matter of claim 3, wherein said adjuvant is a saponin, GM-CSF, or an interleukin.

5. The isolated protein of claim 1, wherein the isolated nucleic acid molecule consists of SEQ ID NO:1.

6. The isolated protein of claim 1, wherein the isolated nucleic acid molecule consists of SEQ ID NO:2.

7. The isolated protein of claim 1, wherein the isolated nucleic acid molecule consists of SEQ ID NO:3.

8. The isolated protein of claim 1, wherein the isolated nucleic acid molecule consists of SEQ ID NO:4.

9. The isolated protein of claim 1, wherein the isolated nucleic acid molecule consists of SEQ ID NO:5.

10. The composition of matter of claim 2, wherein the nucleic acid molecule consists of the nucleotide sequence set forth in SEQ ID NO: 1.

11. The composition of matter of claim 2, wherein the nucleic acid molecule consists of the nucleotide sequence set forth in SEQ ID NO:2.

12. The composition of matter of claim 2, wherein the at least one nucleic acid molecule consists of the nucleotide sequence set forth in SEQ ID NO:3.

13. The composition of matter of claim 2, wherein the nucleic acid molecule consists of the nucleotide sequence set forth in SEQ ID NO:4.

14. The composition of matter of claim 2, wherein the nucleic acid molecule consists of the nucleotide sequence set forth in SEQ ID NO:5.

* * * * *

FEB 2 2006